Skip to main content
. 2021 May 6;96(7):781–789. doi: 10.1002/ajh.26186

FIGURE 2.

FIGURE 2

Retrospective comparison of survival data in 32 patients with blast phase myeloproliferative neoplasm treated with venetoclax + hypomethylating agent (HMA) vs 26 patients treated with HMA alone vs 69 patients treated with intensive chemotherapy [Color figure can be viewed at wileyonlinelibrary.com]